Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-002128-10
    Sponsor's Protocol Code Number:BP39144
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Temporarily Halted
    Date on which this record was first entered in the EudraCT database:2018-02-06
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-002128-10
    A.3Full title of the trial
    An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Studio di Fase I/II adattativo volto a valutare la sicurezza, l’efficacia, la farmacocinetica e la farmacodinamica di RO7112689 in volontari sani e in pazienti con Emoglobinuria Parossistica Notturna (EPN)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Studio volto a valutare la sicurezza, l’efficacia, la farmacocinetica e la farmacodinamica di RO7112689 in volontari sani e in pazienti con Emoglobinuria Parossistica Notturna
    A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria
    A.3.2Name or abbreviated title of the trial where available
    An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO
    Studio di Fase I/II adattativo volto a valutare la sicurezza, l’efficacia, la farmacocinetica e la f
    A.4.1Sponsor's protocol code numberBP39144
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. HOFFMANN - LA ROCHE LTD.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF.Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasilea
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number0
    B.5.5Fax number0
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code RO7112689/F01
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 1917321-26-6
    D.3.9.2Current sponsor codeRO7112689
    D.3.9.3Other descriptive nameC5 inh MAb, SKY59, RO/CH7092230
    D.3.9.4EV Substance CodeSUB183839
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number170
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Paroxysmal nocturnal hemoglobinuria (PNH)
    Emoglobinuria Parossistica Notturna (EPN)
    E.1.1.1Medical condition in easily understood language
    Paroxysmal Nocturnal Hemoglobinuria is a rare, acquired, life-threatening disease of the blood that leads to the premature death and impaired production of red blood cells
    L’Emoglobinuria Parossistica Notturna è una malattia del sangue rara, acquisita, che mette in pericolo di vita e conduce a morte prematura e compromessa produzione dei globuli rossi
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10055629
    E.1.2Term Paroxysmal nocturnal hemoglobinuria
    E.1.2System Organ Class 100000004857
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part 1
    • Evaluate the safety and tolerability of single doses of RO7112689 in healthy volunteers (HVs)

    Part 2 and 3
    • Evaluate the safety and tolerability of RO7112689 for a total duration of 5 months in treatment naïve patients with PNH and PNH patients switching treatment to RO7112689
    • Evaluate the pharmacodynamic (PD) effect of multiple doses of RO7112689 on complement activity in patients with PNH

    Open Label Extension (OLE)
    • Assess the long term safety of RO7112689
    Parte 1
    • Valutare la sicurezza e la tollerabilità di singole dosi di RO7112689 in volontari sani (HV)

    Parti 2 e 3
    • Valutare la sicurezza e la tollerabilità di RO7112689 per una durata totale di 5 mesi in pazienti con emoglobinuria parossistica notturna (EPN) naïve al trattamento e pazienti con EPN che passano al trattamento con RO7112689
    • Valutare l'effetto farmacodinamico (PD) di dosi multiple di RO7112689 sull'attività del complemento in pazienti con EPN

    Fase estensione in aperto (OLE)
    • Valutare la sicurezza a lungo termine di RO7112689
    E.2.2Secondary objectives of the trial
    Part 1
    • Characterize the PD effects of a single-dose of RO7112689 on complement activity (CA) & other related biomarkers
    • Describe the single-dose pharmacokinetic (PK) profile of RO7112689
    • Assess the bioavailability of subcutaneous (SC) administration of RO7112689

    Part 2 and 3
    • Describe the multiple-dose PK properties of RO7112689 in treatment naïve patients (Pts) with PNH and PNH Pts switching treatment to RO7112689
    • Characterize other PD effects of RO7112689
    • Characterize the exposure-response relationship of RO7112689 following different SC dosing regimens
    • Assess the efficacy, Pt-related outcomes & treatment satisfaction of RO7112689 in treatment naïve Pts with PNH, and/or PNH Pts switching treatment to RO7112689

    Parts 1, 2 and 3
    • Explore the PK/PD relationship of single-ascending & multiple doses of RO7112689 on CA & other related biomarkers
    • Evaluate the immunogenicity of RO7112689 in HVs and in Pts with PNH

    OLE
    • Assess the long term safety of RO7112689
    Parte 1
    •Caratterizzare effetti farmacodinamici (PD) di singola dose RO7112689 su attività complemento (AC) e altri biomarcatori correlati
    •Descrivere profilo farmacocinetico (PK) di singola dose RO7112689
    •Valutare biodisponibilità di somministrazione sottocutanea (SC) RO7112689
    Parti 2 e 3
    •Descrivere proprietà PK di dosi multiple RO7112689 in pazienti (Pz) con EPN naïve al trattamento e Pz con EPN che passano al trattamento con RO7112689
    •Caratterizzare altri effetti PD RO7112689
    •Caratterizzare relazione esposizione-risposta RO7112689 dopo diversi regimi di dosaggio SC
    •Valutare efficacia, esiti relativi ai Pz e soddisfazione al trattamento RO7112689 in Pz con EPN naïve al trattamento e/o Pz con EPN che passano al trattamento con RO7112689
    Parti 1, 2 e 3
    •Esplorare rapporto PK/PD di singole dosi crescenti e dosi multiple RO7112689 su AC e altri biomarcatori correlati
    •Valutare immunogenicità RO7112689 in volontari sani e Pz con EPN
    OLE: Valutare sicurezza lungo termine RO7112689
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Part 1 (HVs only)
    • Healthy male volunteers between the age of 21 and 55 years
    • Neisseria meningitidis vaccination against serogroups B and A, C, W, and Y
    • Subjects with a negative hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody, and HIV test result are eligible for the study
    • Subjects who have been vaccinated against hepatitis B

    Parts 2 and 3 (PNH patients only)
    • Male or female patients between the age of 18 and 75 years
    • Hepatitis B patients can be enrolled if their LFT values are less than 2 xULN and there is no liver function impairment
    • Neisseria meningitidis vaccination in accordance with most current local guidelines or Standard of Care (SOC) for patients at increased risk for meningococcal disease (Part 2)
    • Patient has been vaccinated with Neisseria meningitidis vaccine(s) in accordance with most current local guidelines or SOC for patients at increased risk for meningococcal disease or is being revaccinated if applicable (Part 3)
    • Stable dose for >= 28 days prior to screening of other therapies (immunosuppressant therapy, corticosteroids, iron supplements)
    • Negative pregnancy test for women of childbearing potential

    Part 2 only (currently untreated PNH patients who are candidates for treatment with complement inhibitors only):
    • PNH patients who have not been treated with any complement inhibitor or if previously treated stopped treatment due to lack of efficacy based on a single missense C5 heterozygous mutation

    Part 3 only (PNH patients currently treated with eculizumab only):
    • Patients are adequately controlled based on investigator opinion
    • Patients receive regular infusions of eculizumab

    OLE only - PNH patients:
    • PNH patients who have completed Parts 2 and 3 respectively
    • PNH patients who derived, in the Investigator's opinion, benefit from treatment with RO7112689
    Parte 1 (solo volontari sani)
    • Volontari sani di sesso maschile, di età compresa tra 21 e 55 anni
    • Vaccinazione contro Neisseria meningitidis sierogruppi B e A, C, W e Y
    • Soggetti con risultato negativo del test per antigene di superficie dell'epatite B (HBsAg), anticorpo anti-core dell'epatite B (HBcAb), anticorpo anti-epatite C e HIV sono idonei per lo studio
    • Soggetti vaccinati contro l'epatite B

    Parti 2 e 3 (solo pazienti affetti da EPN)
    • Pazienti di sesso maschile o femminile, di età compresa tra 18 e 75 anni
    • Pazienti con epatite B possono essere arruolati, se i loro valori LFT sono < 2 x ULN e non c'è compromissione della funzionalità epatica
    • Vaccinazione contro Neisseria meningitidis in accordo alle più attuali linee guida locali o agli standard di cura (SOC) per i pazienti a maggior rischio di patologia meningococcica (Parte 2)
    • Pazienti che sono stati vaccinati contro Neisseria meningitidis in accordo alle più attuali linee guida locali o agli SOC per i pazienti a maggior rischio di patologia meningococcica o che hanno ripetuto la vaccinazione, se applicabile (Parte 3)
    • Dose stabile di eventuali altre terapie (terapia immunosoppressiva, corticosteroidi, integratori di ferro) per >= 28 giorni prima dello screening
    • Test di gravidanza negativo per donne in grado di procreare

    Solo Parte 2 (solo pazienti affetti da EPN al momento non in terapia che sono candidati per il trattamento con inibitori del complemento):
    • Pazienti affetti da EPN che non sono stati trattati con nessun inibitore del complemento o che, se trattati in precedenza, hanno interrotto il trattamento a causa della mancanza di efficacia sulla base di una singola mutazione missenso eterozigote di C5

    Solo Parte 3 (solo pazienti affetti da EPN attualmente trattati con eculizumab):
    • Pazienti che sono adeguatamente controllati in base al giudizio dello sperimentatore
    • Pazienti che ricevono infusioni regolari di eculizumab

    Solo OLE (pazienti affetti da EPN)
    • Pazienti con EPN che hanno completato le Parti 2 e 3 rispettivamente
    • Pazienti con EPN che, secondo il giudizio dello sperimentatore, hanno tratto beneficio dal trattamento con RO7112689
    E.4Principal exclusion criteria
    Parts 1, 2, and 3:
    • Known or suspected hereditary complement deficiency
    • History of meningococcal meningitis
    • Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 28 days prior to screening or oral antibiotics within 2 weeks prior to screening and up to first study drug administration
    • History of or currently active primary or secondary immunodeficiency, including known history of HIV infection
    • Evidence of malignant disease including myelodysplastic syndrome, or malignancies diagnosed within the previous 5 years

    Part 1 (HVs only):
    • Any clinically relevant history or the presence of moderate to severe respiratory, renal, hepatic, gastrointestinal, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, or connective tissue disease
    • Any major illness within one month before the screening examination or any febrile illness within 2 weeks prior to screening and up to first study drug administration
    • History or presence of clinically significant electrocardiogram (ECG) abnormalities or cardiovascular disease
    • Congenital or acquired complement deficiency
    • Carriers of Neisseria meningitides based on cultures from naso-pharyngeal swabs

    Parts 2 and 3 (PNH patients only):
    • Evidence of moderate to severe concurrent renal, liver, cardiac, pulmonary or gastrointestinal disease not related to PNH as determined by the Investigator
    • History of bone marrow transplantation
    • Treatment with azathioprine or erythrocyte-stimulating agents within 14 days prior to first study drug administration
    Parti 1, 2 e 3:
    • Deficienza ereditaria del complemento nota o sospetta
    • Anamnesi di meningite meningococcica
    • Qualsiasi episodio maggiore di infezione che richieda ricovero o trattamento con antibiotici (EV) nei 28 giorni che precedono lo screening o con antibiotici per via orale nelle 2 settimane che precedono lo screening e fino alla prima somministrazione del farmaco dello studio
    • Anamnesi di pregressa o attuale immunodeficienza primaria o secondaria attiva, compresa storia nota di infezione HIV
    • Evidenza di neoplasia maligna, compresa la sindrome mielodisplastica, o neoplasie maligne diagnosticate nei 5 anni precedenti

    Parte 1 (solo volontari sani):
    • Qualsiasi anamnesi clinicamente significativa o presenza di patologia respiratoria, renale, epatica, gastrointestinale, ematologica, linfatica, neurologica, cardiovascolare, psichiatrica, muscoloscheletrica o del tessuto connettivo da moderata a grave
    • Qualsiasi malattia maggiore nel mese che precede lo screening o malattia febbrile nelle 2 settimane che precedono lo screening e fino alla prima somministrazione del farmaco dello studio
    • Anamnesi o presenza di anormalità dell'elettrocardiogramma (ECG) clinicamente significative o malattia cardiovascolare
    • Deficienza del complemento congenita o acquisita
    • Soggetto portatore di Neisseria meningitidis in base alle colture dai tamponi naso-faringei

    Parti 2 e 3 (solo pazienti affetti da):
    • Evidenza di malattia concomitante renale, epatica, cardiaca, polmonare o gastrointestinale da moderata a grave non correlata a EPN, come determinato dallo sperimentatore
    • Anamnesi di trapianto di midollo osseo
    • Trattamento con azatioprina o agenti stimolanti gli eritrociti nei 14 giorni che precedono la prima somministrazione del farmaco dello studio
    E.5 End points
    E.5.1Primary end point(s)
    Safety (Parts 1, 2, and 3): 1. Incidence of dose-limiting events 2. Incidence and severity of adverse events (AEs), serious adverse events and AEs leading to withdrawal PD (Parts 1, 2, and 3): 3. Ex vivo liposome lysis in serum and ex-vivo lysis of antibody-coated erythrocytes 4. Total and target engaged C5 concentration 5. Serum LDH
    Sicurezza (Parti 1, 2 e 3): 1. Incidenza di eventi dose-limitanti 2. Incidenza e gravità di eventi avversi (AE), eventi avversi gravi e AE che portano al ritiro PD (Parti 1, 2 e 3): 3. Lisi liposomiale ex vivo nel siero e lisi ex vivo degli eritrociti rivestiti di anticorpi 4. Concentrazione totale e target di C5 occupato 5. LDH sierico
    E.5.1.1Timepoint(s) of evaluation of this end point
    Safety and PD (Parts 1, 2, and 3): 1-5. Approximately 6 months for Part 1; approximately 8 months for Parts 2 and 3
    Sicurezza e PD (Parti 1, 2 e 3): 1-5. Approssimativamente 6 mesi per la Parte 1; approssimativamente 8 mesi per le Parti 2 e 3
    E.5.2Secondary end point(s)
    Efficacy (Parts 2 and 3): 1. Change in LDH 2. Change in free-haemoglobin 3. Proportion of patients with stabilized haemoglobin levels 4. Change in fatigue as measured by the functional assessment of chronic illness therapy fatigue 5. Change in health-related quality of life as measured by the European Organization for Research and Treatment of Cancer quality of life questionnaire-core 30 6. Number of packed RBC units transfused per patient 7. Time to (1) first transfusion or (2) persistent elevation of LDH 8. Proportion of patients with LDH below ULN 9. Proportion of patients with complement suppression throughout the dosing interval

    PK (Parts 1, 2, and 3): 10. Pharmacokinetic profile of RO7112689; Cmax, Tmax, AUC, T1/2, bioavailability following SC administration
    Efficacia (Parti 2 e 3): 1. Cambiamento dei LDH 2. Cambiamento dei livelli di emoglobina libera 3. Proporzione di pazienti con livelli stabilizzati di emoglobina 4. Cambiamento della condizione di affaticamento misurata tramite il functional assessment of chronic illness therapy (FACIT) fatigue 5. Cambiamento della qualità della vita correlata alla salute misurata tramite il questionario sulla qualità della vita core 30 dell’Organizzazione Europea per la Ricerca ed il Trattamento del Cancro 6. Numero di unità di concentrati eritrocitari trasfuse per paziente 7. Tempo fino (1) alla prima trasfusione o (2) all’aumento persistente di LDH 8. Proporzione di pazienti con LDH sotto l’ULN 9. Proporzione di pazienti con soppressione del complemento durante l’intervallo tra le dosi

    PK (Parti 1, 2 e 3): 10. Profilo farmacocinetico di RO7112689; Cmax, Tmax, AUC, T1/2, biodisponibilità a seguito di somministrazione SC
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy and PK (Parts 1, 2, and 3): 1-10. Approximately 6 months for Part 1; approximately 8 months for Parts 2 and 3; up to a maximum of two years from entry into OLE
    Efficacia e PK (Parti 1, 2 e 3): 1-10. Approssimativamente 6 mesi per la Parte 1; approssimativamente 8 mesi per le Parti 2 e 3; fino a un massimo di due anni dall’entrata nella fase OLE
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    France
    Germany
    Hungary
    Italy
    Japan
    Korea, Republic of
    Netherlands
    New Zealand
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months42
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months42
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 40
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 9
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 37
    F.4.2.2In the whole clinical trial 49
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The Sponsor will offer post-trial access to the study drug (RO7112689) free of charge to eligible patients, i.e., patients who derive clinical benefit from RO7112689, in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product. Please see section 4.4.4 of the protocol for further information.
    Il Promotore offrirà gratuitamente ai pazienti elegibili l’accesso post-studio al farmaco dello studio (RO7112689), ossia i pazienti che traggono beneficio clinico da RO7112689, in accordo alla policy globale Roche in tema di accesso continuato al prodotto medicinale in studio. Si prega di fare riferimento alla sezione 4.4.4 del Protocollo, per ulteriori informazioni.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-06-22
    P. End of Trial
    P.End of Trial StatusTemporarily Halted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 00:59:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA